Research Article

Tolerogenic versus Inflammatory Activity of Peripheral Blood Monocytes and Dendritic Cells Subpopulations in Systemic Lupus Erythematosus

Table 1

Clinical findings in 43 patients with systemic lupus erythematosus (SLE).

ASLE ISLE
( 𝑛 = 1 8 )

Mean SLEDAI scores9.7 ± 3.21.6 ± 0.9
Mean time since diagnosis7.6 ± 7.49.0 ± 6.0
Lupus nephritis44.4%61.3%
Neurolupus0%19.4%
Lupus arthritis66.7%58.1%
Haematological involvement100%87.1%
Lupus cutaneous involvement77.8%74.2%
Severe Lupus*44.4%71%
Anti-dsDNA antibodies**
 Low positive11.1%32.3%
 Moderately positive22.2%22.6%
 High positive55.6%6.5%
Treatment
 Hydroxychloroquine94.4%87.1%
 Immunossupressants***66.7%32.3%
 Steroids****83.4%12.9%
 Low dose46.6%100%
 Moderate dose33.3%0%
 High dose20.1%0%

ASLE: Active disease group.
ISLE: Inactive disease group.
*Lupus severity in accordance with cumulative major organ involvement.
**Anti-dsDNA antibodies: low positive (<20 IU); moderately positive (20–50 IU); high positive (>50 IU).
***Azathioprine, mycophenolate mo1etil, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, or rituximab.
****Low dose, upto 10 mg/day; moderate dose, 10–30 mg/day; high dose, more than 30 mg/ day; 𝑛 = sample investigated.